Logo of Argent Biopharma (ASX:RGT)Latest Argent Biopharma (ASX:RGT) News

Page 1
Page 1 of 3

Argent BioPharma licences four cannabis genotypes worldwide in 15% profit deal

Argent BioPharma has granted Thai Phytomed International exclusive global commercialisation rights to four cannabis genotypes under a 10-year agreement. The deal preserves Argent’s ownership, but royalties depend on TPI generating profitable sales and securing approvals across multiple markets.
Victor Sage
27 Oct 2026

Market Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Prominence Energy doubled as hydrogen speculation drove the week’s biggest move, while takeover news lifted RAS Technology and Cleanaway.
Zip Co and several resource developers fell as investors weighed costs, capital needs and delivery risks.
Logan Eniac
24 Oct 2026

Argent BioPharma reports A$11,000 cash as licensing strategy broadens

Argent BioPharma ended the September quarter with just A$11,000 in cash after A$734,000 of operating outflows, despite retaining A$7.4 million of unused convertible financing capacity. The company is simultaneously expanding its commercial portfolio through NLC antiviral rights and a CannEpil veterinary programme.
Victor Sage
23 Oct 2026

Argent BioPharma adds NLC antivirals with sales-linked fees and potential equity

Argent BioPharma has secured exclusive commercialisation rights to selected Tollovir, Tollovid and NutraVir antiviral products in a worldwide deal excluding China. The agreement adds a new commercial pillar alongside CimetrA®, but does not itself grant pharmaceutical development rights or establish clinical efficacy.
Victor Sage
29 Sept 2026

Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.
Logan Eniac
29 Aug 2026

FDA Opens Regulatory Pathway for Argent BioPharma’s CannEpil Veterinary Program

Argent BioPharma has secured a key FDA regulatory milestone with the establishment of an Investigational New Animal Drug (INAD) file for its CannEpil veterinary program, targeting cancer-related pain in companion animals.
Victor Sage
26 Aug 2026

Healthcare Wrap - Week 32 (3 Aug -> 7 Aug) 2026

Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.
Logan Eniac
8 Aug 2026

Argent BioPharma Advances CannEpil® into US Veterinary Market with FDA Pathway

Argent BioPharma's licensing partner Splash Beverage Group has launched the US veterinary development program for CannEpil®, targeting companion-animal oncology and chronic pain. Led by industry veteran Dr Hunter Land, the initiative follows a defined FDA regulatory pathway and could broaden CannEpil®’s commercial footprint beyond human neurology.
Victor Sage
6 Aug 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

Argent BioPharma Cuts US$5.5m Debt with Splash Licensing Deal, Advances Veterinary Assets

Argent BioPharma has eliminated US$5.5 million in secured debt through a global licensing agreement for its CannEpil® epilepsy therapy, while completing a key acquisition and advancing clinical trials in veterinary therapeutics.
Ada Torres
28 July 2026

Healthcare Wrap - Week 28 (6 July -> 10 July) 2026

Healthcare stocks swung hard this week as debt clean-ups, fresh funding and product sales updates drove the biggest moves. The strongest gains came from companies with clear near-term cash or commercial news, while some early spikes faded once trading settled.
Logan Eniac
11 July 2026

Argent BioPharma Licenses CannEpil® Globally to Splash Beverage for US$5.5M Upfront and 15% Royalties

Argent BioPharma has struck a global licensing deal for its CannEpil® epilepsy therapy with Splash Beverage Group, securing US$5.5 million upfront through convertible debt forgiveness and retaining manufacturing and intellectual property rights alongside a 15% royalty on future sales.
Ada Torres
7 July 2026